|
MultiCell
Technologies Obtains Patent Protection in Several European Countries for
Treatment of Autoimmune Diseases
Patent Pushes Company's Intellectual Property Portfolio of
First-in-Class Technologies Past 70 Issued or Pending Patents.
SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc.
(OTCBB:MCET - News), developing
first-in-class drugs based on advanced immune system modulation and other
proprietary technologies, today announced it has obtained patent protection
for their latest issued European patent in several countries, including
France, Germany, Switzerland, U.K., Ireland, Belgium, Luxembourg and
Monaco. This patent covers next generation technology from MCET, targeting
multibillion-dollar medical marketplace segments, including a range of serious
autoimmune disorders such as type-1 diabetes and multiple sclerosis.
The patent, which was issued last month by the European
Patent Office, is a milestone validation of the Company's business strategy
to obtain broad, worldwide protection of its advanced immune modulation
technologies and intellectual property. The patent has helped push the
Company's IP portfolio past the 70 issued or pending patent threshold.
MultiCell is leveraging its breakthrough technology
platforms to develop a new generation of therapeutic candidates which
stimulate or suppress the immune system to treat such conditions as
multiple sclerosis, type-1 diabetes, virally caused cancers, and infectious
disease.
"From its inception, MultiCell has been committed
to competing on the international stage," said Dr. Stephen Chang,
Chief Executive Officer of MultiCell Technologies. "We believe the
issuance of the patent by several European nations further validates our
technology and continues to build value for our shareholders."
The patent, "Compositions for Treating Autoimmune
Disease", leverages MultiCell's proprietary platform technologies for
modulating the immune response to treat a range of serious diseases.
The newly issued patent is related to compositions for
the effective presentation of immunosuppressive factors that are useful for
the treatment of various disorders. The Company's technology platforms
include Toll-like Receptor signaling and T-cell targeting to modulate both
the innate and adaptive immune systems. These technologies enable the
creation of advanced drug candidates that stimulate or suppress the immune
system via disease-specific targeting.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is an integrated
biopharmaceutical company committed to the development of breakthrough
therapeutics based on a portfolio of therapeutic candidates and patented
drug development technology. MultiCell's drug development program is
focused on modulation of the immune system. MultiCell's therapeutic pipeline
includes drug candidates some of which are in various advanced stages of
human clinical trials. These therapies include:
·
MCT-125 for the treatment of chronic fatigue
in MS patients. MCT-125 completed a Phase II clinical trial and
demonstrated significant efficacy in reducing chronic fatigue in MS
patients. There is no drug specifically approved for the treatment of
chronic fatigue in MS patients anywhere in the world.
·
MCT-175 for the treatment of
relapsing-remitting MS. MCT-175, in preclinical development for the
treatment of relapsing-remitting MS, targets disease specific
autoaggressive T-cells that destroy the myelin sheath of nerve cells.
MCT-175 successfully ameliorated the disease in animal models.
·
MCT-275 for the treatment of type-1
diabetes. MCT-275, in preclinical development, targets disease-specific
autoaggressive T-cells that destroy insulin producing cells in the
pancreas. MCT-275 completely reversed the type-1 diabetic phenotype and
prolonged life in animal models.
·
MCT-465 in an adjuvant therapy for the
treatment of virus infection and cancer. MCT-465 in preclinical studies
successfully reduced pulmonary influenza virus levels 1,000-fold in animal
models, and has demonstrated effectiveness in reducing virus levels of HIV
and HCV in animal models. MCT-465 in preclinical studies successfully
eliminated certain types of tumors in animal models.
The Company also holds unique cell-based technology for
use in drug discovery screening applications, and is a leading producer of
the cell lines needed by the biotechnology industry to develop new drugs
and therapeutics.
For more information about MultiCell Technologies,
please visit http://www.MultiCelltech.com.
For investor information about MultiCell, please visit http://www.trilogy-capital.com/tcp/multicell.
For current stock price quotes and news, visit http://www.trilogy-capital.com/tcp/multicell/quote.html.
To view the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/multicell/factsheet.html.
To listen to an archived investor conference call, visit http://www.trilogy-capital.com/tcp/multicell/conference.html.
Forward-Looking Statements
Any statements in this press release about MultiCell's
expectations, beliefs, plans, objectives, assumptions or future events or
performance are not historical facts and are forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995 (the
"Act"). These statements are often, but not always, made through
the use of words or phrases such as "believe," "will,"
"expect," "anticipate," "estimate,"
"intend," "plan," "forecast," "could"
and "would." Examples of such forward-looking statements include
statements regarding developing products that address unmet medical needs.
MultiCell bases these forward-looking statements on current expectations
about future events. They involve known and unknown risks, uncertainties
and assumptions that may cause actual results, levels of activity,
performance or achievements to differ materially from those expressed or
implied by any forward-looking statement. Some of the risks, uncertainties
and assumptions that could cause actual results to differ materially from
estimates or projections in the forward-looking statement include, but are
not limited to, the risk that we might not achieve our anticipated clinical
development milestones, receive regulatory approval, or successfully
commercialize our lead drug candidates as expected, the market for our
products will not grow as expected, and the risk that our products will not
achieve expectations. For additional information about risks and
uncertainties MultiCell faces, see documents MultiCell files with the SEC,
including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2005, and all our
quarterly and other periodic SEC filings. MultiCell claims the protection
of the safe harbor for forward-looking statements under the Act and each
assume no obligation and expressly disclaim any duty to update any
forward-looking statement to reflect events or circumstances after the date
of this news release or to reflect the occurrence of subsequent events.
Contact:
MultiCell Technologies, Inc.
Dr. Stephen Chang, 858.200.0598
MCETInvestor@MultiCelltech.com
or
SmallcapInsights.com
Dr. John Faessel, 858-587-8590
editors@smallcapinsights.com
or
Trilogy Capital Partners (Financial Communications)
Paul Karon, 800-592-6067
paul@trilogy-capital.com
Source: Business Wire (Wednesday November 29, 6:30 am ET)
|
